NZ701601A - Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy - Google Patents

Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Info

Publication number
NZ701601A
NZ701601A NZ701601A NZ70160113A NZ701601A NZ 701601 A NZ701601 A NZ 701601A NZ 701601 A NZ701601 A NZ 701601A NZ 70160113 A NZ70160113 A NZ 70160113A NZ 701601 A NZ701601 A NZ 701601A
Authority
NZ
New Zealand
Prior art keywords
gcc
antibody molecules
targeted therapy
methods
antibodies
Prior art date
Application number
NZ701601A
Other languages
English (en)
Inventor
Helen Alison Frank
Alice A Mcdonald
Theresa L O’Keefe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ701601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ701601A publication Critical patent/NZ701601A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ701601A 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy NZ701601A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27
PCT/US2013/038542 WO2013163633A1 (en) 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Publications (1)

Publication Number Publication Date
NZ701601A true NZ701601A (en) 2016-09-30

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ701601A NZ701601A (en) 2012-04-27 2013-04-27 Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy

Country Status (41)

Country Link
US (3) US9000129B2 (enExample)
EP (1) EP2841575B1 (enExample)
JP (2) JP6472746B2 (enExample)
KR (1) KR102046435B1 (enExample)
CN (1) CN104395470B (enExample)
AR (1) AR090884A1 (enExample)
AU (1) AU2013251312B2 (enExample)
CA (1) CA2871614C (enExample)
CL (1) CL2014002911A1 (enExample)
CO (1) CO7280144A2 (enExample)
CR (1) CR20140497A (enExample)
CY (1) CY1122557T1 (enExample)
DK (1) DK2841575T3 (enExample)
DO (1) DOP2014000242A (enExample)
EA (1) EA034689B1 (enExample)
EC (1) ECSP14028523A (enExample)
ES (1) ES2749181T3 (enExample)
GE (1) GEP201706737B (enExample)
HR (1) HRP20191690T1 (enExample)
HU (1) HUE046404T2 (enExample)
IL (1) IL235307B (enExample)
LT (1) LT2841575T (enExample)
MA (1) MA37569B1 (enExample)
ME (1) ME03560B (enExample)
MX (1) MX362020B (enExample)
MY (1) MY188442A (enExample)
NZ (1) NZ701601A (enExample)
PE (1) PE20142322A1 (enExample)
PH (1) PH12014502399B1 (enExample)
PL (1) PL2841575T3 (enExample)
PT (1) PT2841575T (enExample)
RS (1) RS59370B1 (enExample)
SA (1) SA113340502B1 (enExample)
SG (1) SG11201406855TA (enExample)
SI (1) SI2841575T1 (enExample)
SM (1) SMT201900536T1 (enExample)
TN (1) TN2014000454A1 (enExample)
TW (1) TWI631137B (enExample)
UA (1) UA117910C2 (enExample)
WO (1) WO2013163633A1 (enExample)
ZA (1) ZA201407723B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
WO2015058301A1 (en) * 2013-10-21 2015-04-30 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
JP6496962B2 (ja) 2014-02-14 2019-04-10 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ アセトアミノフェン−タンパク質付加物およびその使用方法
EP3227681B1 (en) 2014-12-03 2020-10-21 Bioventures, LLC Anti-acetaminophen antibodies and acetaminophen protein adducts
US11090383B2 (en) 2015-10-01 2021-08-17 Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
EP3551745A4 (en) 2016-12-12 2020-07-15 Xcella Biosciences, Inc. SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
EP3721372A1 (en) * 2017-12-06 2020-10-14 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
JP2021535180A (ja) * 2018-09-05 2021-12-16 ユニベルシテイト ファン アムステルダム パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用
CA3156776A1 (en) 2019-11-08 2021-05-14 xCella Biosciences, Inc. Apparatus and methods for laser-based single cell recovery from microcapillary arrays
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
US20240059794A1 (en) * 2020-12-17 2024-02-22 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
WO2022216079A1 (ko) * 2021-04-07 2022-10-13 주식회사 엘지화학 Gucy2c 결합 폴리펩타이드 및 그의 용도
AU2023349140A1 (en) * 2022-09-28 2025-04-03 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
AU2023374571A1 (en) 2022-11-01 2025-04-03 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
WO2025061149A1 (zh) * 2023-09-21 2025-03-27 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
CN120965861B (zh) * 2025-10-22 2026-02-13 杭州博茵生物技术有限公司 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
WO1995011694A1 (en) 1993-10-26 1995-05-04 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6602659B1 (en) 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
EP0951475B1 (en) 1996-05-03 2003-07-16 Thomas Jefferson University Metastatic colorectal cancer vaccine
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
EP1274861B1 (en) 2000-03-27 2009-12-23 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
WO2002078683A1 (en) 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1781339B1 (en) 2004-06-25 2013-12-25 Thomas Jefferson University Guanylyl cyclase C ligands
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2188306B1 (en) * 2007-08-10 2016-06-29 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
ES2372236T3 (es) * 2007-11-30 2012-01-17 Genentech, Inc. Polimorfismos de vegf y terapia anti-angiogénesis.
WO2009140436A2 (en) 2008-05-13 2009-11-19 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
ES2559840T3 (es) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2370098A4 (en) * 2008-12-03 2013-07-17 Morphosys Ag Antibodies for guanylyl cyclase receptors
SI2881402T1 (sl) * 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
AU2010217160C1 (en) 2009-02-25 2015-07-02 Diagnocure Inc. Method for detecting metastasis of GI cancer
WO2010104035A1 (ja) * 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
US20120225099A1 (en) 2009-06-15 2012-09-06 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
US9169329B2 (en) * 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
RU2013110780A (ru) * 2010-08-13 2014-09-20 Ф.Хоффманн-Ля Рош Аг Нейропилин в качестве биомаркера для комбинированной терапии бевацизумабом
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
JP2016511257A (ja) * 2013-02-28 2016-04-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与

Also Published As

Publication number Publication date
SG11201406855TA (en) 2014-11-27
IL235307A0 (en) 2014-12-31
DOP2014000242A (es) 2014-11-30
EP2841575A1 (en) 2015-03-04
EA034689B1 (ru) 2020-03-06
SMT201900536T1 (it) 2019-11-13
RS59370B1 (sr) 2019-11-29
PL2841575T3 (pl) 2020-01-31
PH12014502399B1 (en) 2022-04-22
MX362020B (es) 2019-01-04
KR20150004882A (ko) 2015-01-13
CR20140497A (es) 2015-02-10
MA37569B1 (fr) 2020-08-31
TW201348258A (zh) 2013-12-01
UA117910C2 (uk) 2018-10-25
US9273146B1 (en) 2016-03-01
HUE046404T2 (hu) 2020-02-28
EP2841575B1 (en) 2019-06-26
EA201491977A1 (ru) 2015-04-30
ECSP14028523A (es) 2015-09-30
JP6517267B2 (ja) 2019-05-22
CN104395470B (zh) 2018-02-06
JP2017131245A (ja) 2017-08-03
CO7280144A2 (es) 2015-05-29
BR112014026742A2 (pt) 2017-07-11
HK1208049A1 (en) 2016-02-19
CA2871614A1 (en) 2013-10-31
PE20142322A1 (es) 2015-01-25
ES2749181T3 (es) 2020-03-19
LT2841575T (lt) 2019-10-10
MX2014013081A (es) 2015-01-12
WO2013163633A1 (en) 2013-10-31
AU2013251312A1 (en) 2014-10-30
CL2014002911A1 (es) 2015-01-30
PT2841575T (pt) 2019-10-11
TN2014000454A1 (en) 2016-03-30
ME03560B (me) 2020-07-20
MY188442A (en) 2021-12-09
AU2013251312B2 (en) 2018-03-22
JP2015516985A (ja) 2015-06-18
JP6472746B2 (ja) 2019-02-20
CA2871614C (en) 2021-08-31
KR102046435B1 (ko) 2019-11-19
SA113340502B1 (ar) 2015-09-17
AR090884A1 (es) 2014-12-10
EP2841575A4 (en) 2016-06-15
US9000129B2 (en) 2015-04-07
US20160130344A1 (en) 2016-05-12
GEP201706737B (en) 2017-09-25
DK2841575T3 (da) 2019-09-23
HRP20191690T1 (hr) 2019-12-27
SI2841575T1 (sl) 2019-11-29
CY1122557T1 (el) 2021-01-27
IL235307B (en) 2019-07-31
US20130287783A1 (en) 2013-10-31
ZA201407723B (en) 2019-01-30
CN104395470A (zh) 2015-03-04
PH12014502399A1 (en) 2014-12-22
TWI631137B (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
PH12014502399A1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
BR112018005322A2 (pt) anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
EA201791876A1 (ru) Моноклональные антитела к прогастрину и их применение
IL214255B (en) Use of antibodies for preparation of medicaments for treatment of cancer associated with a tumor antigen and methods for diagnosis of cancer associated with a tumor antigen
EA201291260A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
WO2008103645A8 (en) Prostate cancer and melanoma antigens
WO2011015333A3 (en) Targeting of bone marrow neovasculature
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EP2614375A4 (en) COMBINATION METHOD FOR CANCER DIAGNOSIS
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
FR2979346B1 (fr) Nanocorps anti-vcam-1
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
EP2844776A4 (en) CANCER BLOOD TEST USING INSULATED BC200 RNA FROM PERIPHERAL BLOOD FOR THE DIAGNOSIS AND TREATMENT OF INVASIVE BREAST CANCER
EA201001731A1 (ru) Применение радиоактивно меченой молекулы, которая специфически связывается с ed-b фибронектином, в способе лечения лимфомы ходжкина
TH1401006471A (th) โมเลกุลแอนติบอดีต้าน gcc และการใช้โมเลกุลดังกล่าวเพื่อทดสอบภูมิไวรับต่อการรักษาที่มุ่งเป้าไปที่ gcc

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210330

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2023 BY ANAQUA SERVICES

Effective date: 20220322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2024 BY ANAQUA SERVICES

Effective date: 20230322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2025 BY ANAQUA SERVICES

Effective date: 20240320

LAPS Patent lapsed